What is Eikon Therapeutics, Inc. 's additional paid-in capital?

Eikon Therapeutics, Inc. (EIKN) reported additional paid-in capital of $1.55B in Q1 2026.

What does additional paid-in capital mean?

This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.

Eikon Therapeutics, Inc. EIKN Additional Paid-In Capital

Additional Paid-In Capital at other companies

MYR GroupMYRG

$162.37M+6.2%

Travel + LeisureTNL

$4.41B+1.8%

Piper SandlerPIPR

$1B+1.7%

RepligenRGEN

$1.65B+2.2%

Knife RiverKNF

$627.07M+1.0%

AstronicsATRO

$4.9M-96.6%

Other financials

Income statement

See full

Operating income-$87.3M-22.3%

Net income-$83.0M-21.6%

EPS (diluted)-$2.46+90.9%

Balance sheet

See full

Cash & equivalents$161.2M-21.2%

Total debt$254.8M—

Total equity$550.7M+186%

Total assets$850.8M—

Cash flow

See full

Operating cash flow-$89.8M-64.7%

CapEx$262.0K-98.8%

Free cash flow-$90.1M-17.1%

Valuation

See full

Market cap$521.35M—

Where this comes from

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.

The official record: Eikon Therapeutics, Inc. ’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eikon Therapeutics, Inc. 's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Eikon Therapeutics, Inc. 's additional paid-in capital?: Eikon Therapeutics, Inc. (EIKN) reported additional paid-in capital of $1.55B in Q1 2026.
What does additional paid-in capital mean?: This represents the excess amount paid by investors for common shares over their par value. It is a key component of shareholders' equity that captures the capital raised through equity offerings beyond the nominal value of the stock. It reflects the historical market premium at which the company has issued its shares.